



Press Release

Friday, July 31, 2015

Strides Arcolab Limited
Strides House, Bannerghatta Road,
Bangalore – 560076.

BSE: 532531

NSE: STAR

Strides Arcolab receives ANDA approval from US FDA for Benzonatate Softgel Capsules

Product to be launched immediately

Bangalore, July 31, 2015: Strides Arcolab Limited today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Benzonatate Capsules USP, 100 mg and 200 mg.**

According to IMS data, the US market for Benzonatate is approximately USD 41 Million.

The product will be manufactured at the Company's Oral dosage facility at Bangalore and marketed by Strides in the US Market. The product will be launched immediately.

About Benzonatate

Benzonatate is used to treat coughs caused by the common cold and other breathing problems (e.g., pneumonia, bronchitis, emphysema, asthma). It works by reducing the reflex in the lungs that causes the urge to cough.

About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products. The Company has 8 manufacturing facilities presence in more than 75 countries in developed and emerging markets. Additional information is available at the Company's website at www.stridesarco.com. For further information, please contact:

Strides Arcolab Limited	PR Consultancy – Fortuna PR
Mohan Kumar, CEO – Pharma: +91 80 6784 0748	K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.in
Vikesh Kumar: +91 80 6784 0827	K Priya: +91 9535425418, priya@fortunapr.in
Sandeep Baid: +91 80 6784 0791	
Kannan N : +91 98450 54745	

